Since the identification of osteoporosis as a major health issue in aging populations and the
subsequent development of the first treatment modalities for its management, considerable …

Postmenopausal osteoporosis is a disease of high bone remodeling, with an imbalance of
bone resorption over bone formation, resulting in decreased bone mineral density and …

Osteoporosis is a worldwide health problem with a high prevalence. Agents for the treatment
of osteoporosis are classified as either antiresorptive or anabolic. Antiresorptive agents work …

Osteoporosis is a common disease characterised by a systemic impairment of bone mass
and microarchitecture that results in fragility fractures. With an ageing population, the …

Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …

Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal
osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and …

Highlights•Selective cathepsin K inhibition inhibits bone resorption in clinical and preclinical
studies.•Wnt signaling promotes bone formation.•Blockade of Wnt inhibitors increases bone …

For the prevention of fractures, antiresorptive drugs (bisphosphonates and denosumab) that
decrease high bone resorption and, secondarily, also bone formation, are the mainstream of …

Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture
which leads to increased fracture risk. Some of the drugs available to date have shown …

Treatments for osteoporosis over the last few decades have largely focused on
antiresorptive agents that effectively prevent bone loss. Beginning with hormone therapy, a …